Soligenix All Set To Join Russel Microcap Index

Soligenix has announced that the company is all set to join the Russel Microcap Index at the conclusion of the 2020 Russell indexes annual reconstitution, which would be effective after the US markets open on June 29, 2020.

It clearly means that membership of Russel Microcap Index means automatic inclusion in value style indexes and appropriate growth. The Russel Microcap Indexes are widely used by the institutional investor and investment managers for benchmark and index funds for active investment strategies.

FTSE Russel is a global provider of a wide range of indexes, analytics and data solutions to meet the requirement of clients across strategies, styles and classes. It covers 98% of the investable market. The company’s product and services are used extensively by the global retail and institutional investors. The company also provides its clients with different multipurpose tools for different purposes such as, risk management, investment strategy analysis and asset allocation.

Chief Executive Officer and President of Soligenix, Christopher Schaber said, “We are pleased to be included in the Russell Microcap® Index. We anticipate that our addition to the index will increase our visibility to the investment community as we continue to move forward with our programs.”

“After observing a statistically significant treatment response in the double-blind, placebo controlled Cycle 1 portion of our pivotal Phase 3 FLASH (Fluorescent Light Activated Synthetic Hypericin), the trial continues to demonstrate highly statistically significant results and confirm SGX301’s potential to be an important new treatment for early-stage cutaneous T-cell lymphoma,” Christopher Schaber added.

“We also continue to advance our pivotal Phase 3 clinical trial of SGX942 (dusquetide) for the treatment of oral mucositis in patients with head and neck cancer receiving chemoradiation therapy, where we anticipate top-line results in the fourth quarter of 2020,” Christopher Schaber concluded.

Leave a Reply

Your email address will not be published. Required fields are marked *